This study was undertaken to determine the biological activity and/or
toxicity of recombinant human insulin-like growth factor-1 (rHulGF-1)
in cats, and to examine the effects of rHulGF-1, with and without zido
vudine (azidothymidine, AZT) in cats experimentally infected with feli
ne immunodeficiency virus (FIV). A single dose of rHulGF-1, administer
ed intravenously, suppressed blood glucose levels to less than 40 mg/d
l in noninfected cats. When administered to such cats for 30 days, rHu
lGF-1 produced no significant changes in bodyweight, blood cell count,
or plasma chemistry values. There were, however, significant increase
s in thymic (p = 0.0216) and splenic (p = 0.0459) weights in treated c
ats. Subcutaneous administration of rHulGF-1 to FIV-infected cats did
not produce an increase in circulating levels of FIV DNA or anti-FIV a
ntibody, but did result in a significant (p = 0.04) primary antibody r
esponse to a T-cell-dependent immunogen. The administration of AZT, wi
th or without rHulGF-1, produced a dose-related, reversible anemia and
neutropenia.